

MICROBIOME & PROBIOTICS R&D **& BUSINESS COLLABORATION** **FORUM: EUROPE**

ROTTERDAM, THE NETHERLANDS

— 1 8 - 2 0 M a y 2 0 2 0 —



#MicrobiomeForum

www.global-engage.com



Global Engage is pleased to announce the 7th Microbiome & Probiotics R&D and Business Collaboration Forum, due to be held for 3 days between May 18-20 2020 at the Postillion Convention Centre, World Trade Centre, Rotterdam.

This world-renowned event brings together more than 400 industry, academic, and investment leaders to discuss the most cutting-edge microbiome and probiotics research, challenges and opportunities in moving research towards commercialisation, and partnerships and collaborations. This year, the meeting will focus is on the dedicated microbiome themes outlined below as well as the tracks dedicated to Pro/Prebiotics and Skin & Cosmeceuticals:

Microbiome & Probiotics R&D and Business Collaboration Forum				
	Room 1	Room 2	Room 3	Room 4
Day 1	IBD, Colitis, Metabolic Diseases	Women's Health	Probiotics & Prebiotics	Skin & Cosmeceuticals
Day 2	Gut-Brain Axis	Diagnostics & Microbiome Biobanks	Personalised Nutrition	Skin & Cosmeceuticals
Day 3	Cancer	Business Collaboration - Regulations and Investment	Early Life and Infant	Microbiome Tools and Technologies

With a 100-strong speaker faculty, expert-led roundtables and interactive panel sessions, this year's event promises to deliver ample content on the key challenges faced by both researchers and product developers, and the strategies that turn science into viable products with the backing of investors to fund the transition; and with over 8 hours of networking time, there will be numerous opportunities to showcase your work and to broaden your connections in this fast-growing field. The event is widely recognized for its comprehensive agenda and is gaining a fantastic reputation as the number one microbiome networking event. If you're looking to learn more from the top scientists in the microbiome and probiotic space, to showcase exciting developments in your research, or to seek partnerships and funding within the industry, then this meeting is not to be missed.

Platinum Sponsor



Gold Sponsors



Silver Sponsors



Bronze Sponsor



Other Exhibitors & Sponsors



Pen & Pad Sponsor



Content Sponsors

SPONSORSHIP & EXHIBITION OPPORTUNITIES AVAILABLE

For more details contact Gavin Hambrook: gavin@globalengage.co.uk or call +44 (0) 7538 368 764

MICROBIOME SPEAKERS



KAREN NELSON
President, J. Craig Venter
Institute, USA



PAUL WILMES
Associate Professor of
Systems Ecology, University
of Luxembourg



GREGORY BUCK
Professor, Microbiology
& Immunology &
Computer Science, Virginia
Commonwealth University



RIKKE NIELSEN
CEO and Founder, Beo
Therapeutics



DUCCIO CAVALIERI
Professor of Microbiology,
University of Florence



FLORENCE SEJOURNE
CEO, Da Volterra



LIISA LEHTORANTA
R&D Manager, Nutrition &
Biosciences, DuPont



**HENRIK BJØRN
NIELSEN**
CSO, Clinical Microbiomics



YUANYUAN CHEN
Sales Director, Novogene



**SENIOR
REPRESENTATIVE**
DNA Genotek



MARIA AKERMAN
Director Process R&D,
Oxthera, Sweden



MARIE DRAGO
Founder, Gallinée



EDWARD GREEN
Chief Executive, CHAIN
Biotechnology Ltd.



HANA JANEBDAR
Founder and CEO, Juno Bio



SCOTT OLESEN
Scientific Director, OpenBiome



EVELIINA MUNUKKA
Research Director, Turko
Microbiome Biobank, University
of Turku, Finland



EMERAN MAYER
Director, UCLA



AARON DEL DUCA
Head, Microbiome Platform



ALETTA KRANEVELD
Professor Interdisciplinary
Translational Pharmacology,
University of Utrecht, The
Netherlands



MOMO VUYISICH
CSO, Viome, USA



PIERRE LESTAGE
CEO, Neribiom, France



FINN TERJE HEGGE
CTO and Head of Operations,
Genetic Analysis AS



GEORGE TETZ
CEO, Human Microbiology
Institute



KRISTOFER COOK
CEO, Carbiotix



BENJAMIN LELOUVIER
CSO, Vaiomer



OLA TUVESSON
Head of Process Development
and Support, Cobra Biologics



FRANCOIS BIDET
Vice-President of Business
Development, CSP
Technologies



SARITA DAM
PhD Candidate in Translational
Psychiatry, Radboud University
Medical Centre Nijmegen




NICOLETTA DI SIMONE
Professor Obstetrics and
Gynecology, Catholic
University, Rome, Italy



GEOFF BRIGGS
Technology Scout (Devices &
Diagnostics), Walgreen Boots
Alliance



YEMI ADEOKAN
Co-Founder and CSO,
GNUbiotics



OLGA A. PARTINGTON
Counsel, Sterne, Kessler,
Goldstein & Fox P.L.L.C.



LARS ENGSTRAND
Professor, Director Clinical
Genomics Facility & Centre
for Translational Microbiome
Research, Karolinska Institutet,
Sweden



**KRISTIN
WANNERBERGER**
Director R&D Alliance
Management, Ferring
Pharmaceuticals, Switzerland



HOK BING THIO
Erasmus University Medical
Center



MALCOLM KENDALL
Co-Founder & CEO,
Microbiome Insights, Inc



ERIC DE LA FORTELLE
Venture Partner, Seventure
Partners



ROMAIN DAILLÈRE
Head of Preclinical Research,
EverImmune



SIMONE MACCAFERRI
Senior Research Advisor,
Bioeconomy - Research and
Competitive Funding Division,
Alma Mater Studiorum
Università di Bologna, Italy



EDWIN ABELN
Senior Business Development
Manager, TNO



COLETTE SHORTT
Director Global Regulatory
Affairs, J&J Consumer

MICROBIOME SPEAKERS



LISA MACFARLANE
Co-Founder, The Gut Stuff



ALANA MACFARLANE
Co-Founder, The Gut Stuff



ROBERTO GRAU
Assistant Professor, School of Biochemistry and Pharmacy, National University of Rosario, Argentina



JULIA KAPPEL
Customer Success Associate, Zymo Biomics



ARNE MATERNA
Vice President of Product, CosmosID



FRANCO VICARIOTTO
Specialist Obstetrics and Gynecology, Senior consultant of San Pio X Hospital Milan, Italy



KAITLIN WADE
Elizabeth Blackwell Institute Research Fellow in Integrative Epidemiology, University of Bristol, UK



SANDRINE CLAUS
CSO, LNC Therapeutics



QUN WANG
Primary Reviewer, Office of Vaccines Research and Review Center for Biologics Evaluation and Research, U. S. Food and Drug Administration



DAVID HUGHES
Lecturer / Assistant Professor, Cancer Biology and Therapeutics Group, UCD Conway Institute, University College Dublin

PROBIOTICS SPEAKERS



PHILIPPE LANGELLA
Research Director, Laboratory of Commensals and Probiotics-Host Interactions, INRA, France



ANITA FRAUWALLNER
CEO, Institut Allergosan



SHAHRAM LAVASANI
Founder & CEO, ImmuneBiotech



AUBREY LEVITT
CEO, Postbiotics+



MARIO GUSLANDI
Consultant Gastroenterologist, S.Raffaele Hospital, Adjunct Professor of Gastroenterology, S.Raffaele University, Milan, Italy



GRÉGORY LAMBERT
CEO and VP of R&D, TargEDys



MARK O'MAHONY
Technology Scout (Devices & Diagnostics), Walgreen Boots Alliance



MARIA JENMALM
Professor of Experimental Allergology, Linköping University




ARJAN NARBAD
Quadram Institute



JASON BUSH
Adjunct Professor, Department of Biology, Brandon University, USA



SATU PEKKALA
Academy of Finland Research Fellow, Adjunct professor, University of Jyväskylä



PAULO REFINETTI
CEO and Founder of REM Analytics



JEAN-POL WARZEE
President, European Scientific League for Probiotics - ESLP



GER RIJKERS
Professor in Biomedical and Life Sciences, University of Roosevelt, The Netherlands



MIGUEL GUEIMONDE FERNÁNDEZ
Research Scientist, IPLA-CSIC



YEMI ADESOKAN
Co-Founder and CSO, GNUbiotics



CAROLINE CHILDS
Lecturer in Nutritional Sciences, University of Southampton



LYDIA MAPSTONE
CEO, BoobyBiome



MIKE ROGERS
CEO, TrooFoods



DAVID KYLE
Chairman and CSO, Evolve Biosystems



AARON DEL DUCA
Head, Microbiome Platform, DayTwo



OLAF LARSEN
Senior Manager Science, Yakult Nederland B.V., Associate Professor, Vrije Universiteit Amsterdam



MONIKA SCHAUBECK
Nutritional Scientist, Team Science, Department Research and Development, HiPP



THOMAS DAWSON
Senior Principal Investigator,
Skin Research Institute
Singapore, Agency for
Science, Technology and
Research and Affiliated Professor, Department
of Drug Discovery, School of Pharmacy,
Medical University of South Carolina, USA



CATH O'NEILL
Professor of Translational
Dermatology, University
of Manchester and CSO,
SkinBiotherapeutics plc.



INGMAR CLAES
CSO, Yun Probiotherapy



MIREILLE VEGA
VGAM Biosciences, Bridging
Life and Science



ALEX CHAPMAN
Head of Operations, Labskin



JENNIFER POWERS
Assistant Professor of
Dermatology, University of
Iowa, USA



SØREN KJAERULFF
CEO, Lactobio



**SENIOR
REPRESENTATIVE**
Clinical Microbiomics



MIKE HOPTROFF
Senior R&D Manager, Unilever



MIRCEA PODAR
Distinguished Scientist and
Group Leader, Systems
Genetics, Oak Ridge National
Laboratory



MARK WEBBER
Group Leader, Quadram
Institute



MATTHEW GERDING
Investigator II, Novartis Institute
for BioMedical Research (NIBR)



LEO MELCHERS
Strategic Partnerships,
Biosortia Pharmaceuticals



**JONATHAN
FRIEDMAN**
Senior Lecturer, Department
of Plant Pathology and
Microbiology, Hebrew
University, Israel



**JOHAN BENGTTSSON
PALME**
Assistant Professor, Centre
for Antibiotic Resistance
Research, Institute of
Biomedicine, University of
Gothenburg, Sweden



CHRISTINE LANG
Chief Scientific Officer,
Belano Medical AG



LIONEL BRETON
Scientific Director, L'Oréal
Advanced Research



RADHIKA BONGONI
Business Developer,
BaseClear B.V.



IHAB BOULAS
Former CEO, Unibiome



VERONIKA OUDOVA
Co-Founder, S-Biomedic,
Belgium



INGE LINDSETH
Expert Nutrition,
MyMicrobiome



ARNE MATERNA
Vice President of Product,
CosmosID



PIM GAL
Senior Clinical Scientist, Centre
for Human Drug Research
(CHDR), The Netherlands



MILANA ANASH
CEO, Founder, ClearSkin

08:20-08:50 Room: Shipping Hall Registration & Refreshments

MICROBIOME R&D & BUSINESS COLLABORATION

Room: Diamond Room I&II

Global Engage Welcome Address and Morning Chair's Opening Remarks



KEYNOTE ADDRESS: KAREN NELSON
President, J. Craig Venter Institute, USA

09:00-09:40



PAUL WILMES
Associate Professor of Systems Ecology, University of Luxembourg
Systems ecology of host-microbiome interactions

- Integrated multi-omics of microbiome samples
- Different functions expressed in health compared to disease
- Mechanistic understanding of causal relationships

09:40-10:10

PROBIOTICS & PREBIOTICS

Room: Goudriaan room I&II

Global Engage Welcome Address and Morning Chair's Opening Remarks



KEYNOTE ADDRESS: PHILIPPE LANGELLA
Research Director, Laboratory of Commensals and Probiotics-Host Interactions, INRA, France

09:00-09:40



MARIO GUSLANDI
Consultant Gastroenterologist, S.Raffaele Hospital, Adjunct Professor of Gastroenterology, S.Raffaele University, Milan, Italy
Treating chronic intestinal disorders with probiotics

09:40-10:10

Probiotics are potentially helpful in chronic intestinal disorders, where there is an imbalanced composition of the gut microbiota (dysbiosis). This applies, for instance, to irritable bowel syndrome (IBS) and symptomatic, uncomplicated diverticular disease (SUDD). IBS is a multi-factorial condition the symptoms of which can be partially related to dysbiosis (reduced fecal amount of Lactobacilli, Bifidobacteria and F.prausnitzii). Although trials with probiotics have employed different products and doses, various meta-analyses have concluded that probiotics as a group (especially Bifidobacteria) are useful in ameliorating symptoms. SUDD is largely depending on the gut microbiota. An increase in the amount and in the diversity of Enterobacteriaceae have been described, while different types of dysbiosis are linked to different symptoms. Open studies suggest that probiotics may help to prevent development of acute diverticulitis, but controlled trials are lacking. On the other hand controlled studies with probiotics + mesalazine indicate a superior efficacy over the single agents and placebo.

SKIN & COSMECEUTICALS

Room: Leeuwen room I&II

Global Engage Welcome Address and Morning Chair's Opening Remarks



KEYNOTE ADDRESS: THOMAS DAWSON
Senior Principal Investigator, Skin Research Institute Singapore, Agency for Science, Technology and Research and Affiliated Professor, Department of Drug Discovery, School of Pharmacy, Medical University of South Carolina, USA

09:00-09:40

Role of eukaryotic microflora in skin disease and skin health homeostasis
The vast majority of "microbiome" data remains "bacteriome". In human skin, the mycobiome is a key player which cannot be ignored. The distribution of fungal DNA, the size of fungal cells (biomass per genome), immunological profiling (and the IL-17 response), and clinical treatment indicate that fungi are a key aspect of healthy skin homeostasis and are ignored at the researchers peril. We have shown significant differences in the composition of skin microbiome related to geography and ethnicity, and are building Asia specific data to enable modulation of the skin microbiome to improve skin health.

09:40-10:10



CATH O'NEILL
Professor of Translational Dermatology, University of Manchester and CSO, SkinBiotherapeutics plc.
Lactobacilli in topical products: choosing the right species for the job

Lactobacilli have been used in cosmetic products for years. In this presentation, I will explore the different activities of various species of lactobacilli and show why the 'right species for the right job' should be used. In particular, I will describe my work using lysates from L. rhamnosus GG to improve skin barrier function, showing development of this from basic studies in the laboratory, to a clinical study.

10:10-10:40



ARNE MATERNA
Vice President of Product, CosmosID



10:10-10:40

30-Minute Solution Provider Presentation
For sponsorship opportunities please contact Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

10:10-10:40



CHRISTINE LANG
Chief Scientific Officer, Belano Medical AG

10:40-11:50 Room: Shipping Hall Morning Refreshments / One-to-One Meetings / Odd Numbered Poster Presentations

Room: Diamond Room I&II

IBD, COLITIS, METABOLIC DISEASES



SANDRINE CLAUS
CSO, LNC Therapeutics
Restoring gut Microbiome functions using keystone single strain bacteria in the treatment of metabolic disorders

Gut microbiome dysbiosis is associated with a number of metabolic disorders, such as obesity and related co-morbidities. In situations where a causal link between specific microbes and important phenotypic traits has been established, it makes sense to use a microbiome-based therapeutic strategy to restore altered or missing functions. Here we will discuss how using rationally selected keystone single strain bacteria can be used as a novel therapeutic approach.

11:50-12:15



RIKKE NIELSEN
CEO and Founder, Beo Therapeutics
Microbial treatments for gout and metabolic diseases

- Screening and lead selection of microbial therapy for hyperuricemia
- Pre-clinical development, biomarkers and translation into the clinic
- Product classes and commercialisation of microbiome therapies

12:15-12:40



FLORENCE SEJOURNE
CEO, Da Volterra
Protecting and preserving the intestinal microbiota from antibiotic-induced dysbiosis

- with an antibiotic quencher: an effective and safe solution for the prevention of Clostridioides difficile infection**
- DAV132, a microbiota protective therapy that quenches the impact antibiotic residues in

12:40-13:05

Room: Van Oldenbarnevelt Room

WOMEN'S HEALTH



LIISA LEHTORANTA
R&D Manager, Nutrition & Biosciences, DuPont
Vaginal Microbiota Management and Impact on Women's Health

- Outline the importance of vaginal microbiota on health
- Overview of current and future trends on vaginal microbiota research
- Explore the ways how to beneficially modulate vaginal microbiota to improve health

11:50-12:15

DUCCIO CAVALIERI
Professor of Microbiology, University of Florence
Beyond the bacteriome - vaginal and gut mycobiome and inflammatory balance

12:15-12:40



MARIE DRAGO
Founder, Gallinée
Topic: Vaginal Microbiome

12:40-13:05

Room: Goudriaan room I&II

PROBIOTICS & PREBIOTICS



SHAHRAM LAVASANI
Founder & CEO, ImmuneBiotech
Targeting the brain-gut-microbiome axis by ImmuneBiotics™, a new therapeutic avenue for management of autoimmunity

- Brain-gut-microbiome axis; potential therapeutic targets and probiotic treatments
- Designing multi-targeted therapeutic microbial consortium; translational success for GutMagnific™ in management of IBS
- ImmuneBiotics™, new generation of probiotic products designed to boost the immunotherapy treatments

11:50-12:15



CAROLINE CHILDS
Lecturer in Nutritional Sciences, University of Southampton
Probiotics, prebiotics and the immune system

- How does the gut microbiota interact with the development of the immune system, particularly during early life?
- The leaky gut - causes and consequences
- The role of nutrition in directly modulating the immune system

12:15-12:40



AUBREY LEVITT
CEO, Postbiotics+
Postbiotics, why we believe they are probiotics 2.0

- Our clinical research, from metabolites to gut modeling to in the clinics with patients
- What are postbiotics and why they are important
- How postbiotics enhance probiotics

12:40-13:05

Room: Leeuwen room I&II

SKIN & COSMECEUTICALS



INGMAR CLAES
CSO, Yun Probiotherapy
A topical cream with encapsulated 'live' lactobacilli clinically improve acne symptoms

- New dermatological approach to antibiotics in reducing acne symptoms - positioning within acne guidelines
- Selection of Lactobacillus strains to beneficially impact the skin microbiota
- YUN's encapsulation technology ensuring the viability of beneficial bacteria in water based formulations
- Case studies of use of live lactobacilli in other dermatological conditions

11:50-12:15

SABRINA LEOTY-OKOMBI (Reserved)
R&D Project Leader, BASF
Topic: Healthy Skin

12:15-12:40

MIREILLE VEGA
Founder, VGAM Biosciences
Optimized Growth Medium for a Healthy Skin Microbiota: a balanced review of prebiotic and postbiotic approaches

12:40-13:05

12:40-13:05


the colon, is able to preserve the intestinal microbiota, in a Phase 2 clinical study conducted in 260 patients

- The understanding of DAV132 profile in humans is reinforced by a series of studies in healthy subjects including microbiome analysis
- Additional animal model translation work will also be presented


12:40-13:05

Continue

13:05-13:35




HENRIK BJØRN NIELSEN
CSO,
Ultrahigh resolution microbiomics and integrative systems biology



Clinical-Microbiomics offers custom-tailored microbiome research as a service, including data-generation and bioinformatics analysis. Here we present our framework for ultra-high resolution (UHR) microbiomics. UHR microbiomics allows us to accurately profile the microbial composition of samples and to build phylogenetic trees that relate sub-species populations across samples and subjects. Phylogenetic trees elegantly condense vast amounts of details into simple data-structures that can be used for statistical analysis and for deriving functional insights. Moreover, it allows us to track therapeutic strains, to monitor microbial population dynamics, and even to gain insight to microbial inheritance of accessory genes.

13:05-13:35



YUANYUAN CHEN
Sales Director, Novogene

12:40-13:05

- Why postbiotics have the potential to be utilized as adjunct therapies


12:40-13:05

Continue

13:05-13:35

30 Minute Solution Provider Presentation
For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk / +44 (0) 1865 849841

13:05-13:35



ALEX CHAPMAN **LABSKIN**
Head of Operations, Labskin
Labskin-AI, a Human Skin Equivalent for the Investigation of Skin Dysbiosis

Labskin is a full thickness human skin model. The Labskin epidermis has a dry surface with an effective barrier function that allows colonisation by human skin microflora (individual commensal and pathogens, microbial consortia and whole microbiomes isolated from volunteers). This allows us to mimic skin diseases such as acne, seborrheic dermatitis, atopic dermatitis or psoriasis. We use AI technology to identify features characterising healthy and dysbiotic skin states that can detect shifts in the microbiome after topical treatment. Active ingredients and formulations can be tested to study their effects on the skin and the colonising microflora. We measure multiple endpoints via viable counting, ELISA, histology & immunohistochemistry, metagenomics, proteomics and transcriptomics.

13:35-14:35 Room: Shipping Hall Lunch / One-to-One Meetings

14:35-14:50

IBD, COLITIS, METABOLIC DISEASES

POSTER COMPETITION WINNER TALKS:
If interested in submitting a poster and/or applying to present a poster on the programme, please [CLICK HERE](#) and apply before the deadline 27th April 2020

14:35-14:50

WOMEN'S HEALTH

POSTER COMPETITION WINNER TALKS:
If interested in submitting a poster and/or applying to present a poster on the programme, please [CLICK HERE](#) and apply before the deadline 27th April 2020

14:35-14:50

PROBIOTICS & PREBIOTICS

POSTER COMPETITION WINNER TALKS:
If interested in submitting a poster and/or applying to present a poster on the programme, please [CLICK HERE](#) and apply before the deadline 27th April 2020

14:35-14:50

SKIN & COSMECEUTICALS

POSTER COMPETITION WINNER TALKS:
If interested in submitting a poster and/or applying to present a poster on the programme, please [CLICK HERE](#) and apply before the deadline 27th April 2020

14:50-15:05



SENIOR REPRESENTATIVE

Biose

15:05-15:20



SENIOR REPRESENTATIVE

Luina Bio

15:20-15:45



MARIA AKERMAN

Director Process R&D, Oxthera, Sweden

Unlocking the potential of the microbiome: Oxalobacter formigenes for the treatment of Primary hyperoxaluria

- OxThera pursues the development of Oxabact®, a live biotherapeutic drug made of lyophilized Oxalobacter formigenes.
- To date, OxThera has completed three double-blinded phase II/III clinical studies with different formulations (OC3 and OC5) and are currently pursuing a fourth multicenter, international, double-blinded phase III clinical trial investigating the safety and efficacy of the improved Oxabact® formulation, OC5 in Primary hyperoxaluria patients with maintained renal function.
- Confirmation of long-term efficacy and safety is now underway through the ongoing phase III, double-blind, placebo-controlled study, where subjects are being randomized 1:1 to receive either OC5 or placebo, and are offered to pursue a long-term follow up study to prove clinical benefit.

14:50-15:05

15 Minute Solution Provider Presentation
For sponsorship opportunities please contact
Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

15:05-15:20



SENIOR REPRESENTATIVE

Life and Soft

15:20-15:45

HANA JANEBDAR

Founder and CEO, Juno Bio

Topic: Vaginal Microbiome

14:50-15:20



SENIOR REPRESENTATIVE

Probiotal

15:20-15:45



GRÉGORY LAMBERT

CEO and VP of R&D, TargEDys

Modulating the appetite through the probiotic strain Hafnia alvei HA4597

TargEDys is a French clinical stage biotech company aiming to control metabolic disease by modulating the appetite through an intervention on the microbiome. TargEDys' innovative, satiety inducing technology (ProbioSatys®), is based on a unique understanding of appetite regulation by the microbiome at the molecular level. Bacteria can send signals of satiety to the brain from the gut by molecularly mimicking satiety hormones, thus activating natural satiety pathways. The basis of the technology is a commensal, enterobacteria probiotic strain, Hafnia alvei HA4597™, that produces the ClpB protein, a mimetic of the satiety hormone α-MSH. The pre-clinical data have demonstrated the beneficial anti-obesity effects of Hafnia alvei 4597™ in mice. Treatment with Hafnia alvei4597™ was associated with decreased body weight and fat mass gain along with reduced food intake as well as positive effects on glycemia and OGTT. A randomised, multicentric, double-blind, placebo controlled clinical trial in 240 subjects has been completed. The trial met the primary endpoint: statistical difference in the proportion of subjects who lost at least 3% of body weight at 12 weeks. Amongst other findings, the mechanism of action is confirmed by achieving secondary endpoints such as an increase in the feeling of fullness in the verum group. This talk covers ProbioSatys® journey from its preclinical and clinical stage to commercialized product, EnteroSatys®, including formulation, manufacturing and control. First results of clinical trial will be presented and discussed.

14:50-15:20




ARNE MATERNA



Vice President of Product, CosmosID

15:20-15:45



JENNIFER POWERS

Assistant Professor of Dermatology, University of Iowa, USA

Microbiome Trends in Cutaneous Scar Formation

Chronic wounds and scars create huge healthcare expenditures. There are huge knowledge gaps related to the extent to which bacteria potentiate abnormal wound healing. Our research seeks to explore the connection between the cutaneous microbiome, the immune system, and clinical scarring outcomes with an eye towards therapeutic applications.



EDWARD GREEN
Chief Executive, CHAIN
Biotechnology Ltd.
**Next Generation Live
Biotherapeutics**

- CHAIN develops superior live biotherapeutic products based on Clostridia bacteria.
- Our bacteria are precision engineered to produce specific therapeutic molecules in the human gut.
- Our unique engineering capability supports a pipeline of therapeutic candidates addressing multiple disease areas associated with the human gut microbiome.

15:45-16:10



FRANCO VICARIOTTO
Specialist Obstetrics and
Gynecology, Senior consultant of
San PIO X Hospital Milan, Italy
**The rationale of probiotics in
urogenital female healthcare**

The human vaginal microbiota plays an important role in the maintenance of a woman's health, as well as of her partner and newborns. When this predominantly Lactobacillus community is disrupted or decreased in abundance, Vaginitis may occur. Of the millions of cases of vaginitis, most are caused by bacterial vaginosis (BV), followed by Vulvovaginal candidiasis (VVC). BV is associated with ascending infections and obstetrical complications, such as chorioamnionitis and preterm delivery. Therapy with oral or local recommended antibiotics is often associated with failure and high rates of recurrences. (Antibiotics can not always penetrate the pathogenic biofilm) The dominance of lactobacilli in healthy vaginal microbiota and its depletion in BV and VVC has given rise to the concept of oral or vaginal use of probiotic strains for treatment and prevention of vaginitis and to prevent pregnancy disease

15:45-16:10



ANITA FRAUWALLNER
CEO, Institut Allergosan
**How high quality probiotics
improve our customers' lives
and our companies' healthy
development**

The human microbiota has become the focus of medical research in the 21st century. Pre, pro- and synbiotic treatment is able not only to strengthen the gut barrier function, which ultimately restores many dysfunctions in elderly as well as in newborns, but also is highly effective to improve the gut-brain-axis which is shown in many research articles about depression, migraine, dementia and cognition. But what is good for our customers is even better for those companies that develop these high-quality probiotics - if they are able to market these products in surprising ways, targeting new groups of people which are interested in a modern life style.

15:45-16:10

MICHELE EVRARD (Reserved)
Founder & CEO, M.E.SkinLab
Title TBC

15:45-16:10

16:10-17:00 Room: Shipping Hall Afternoon Refreshments / One-to-One Meetings / Even Numbered Poster Presentations

IBD, COLITIS, METABOLIC DISEASES

17:00-17:30

30 Minute Solution Provider Presentation
For sponsorship opportunities please contact
Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

MICROBIOME BIOBANKS

17:00-17:30

30 Minute Solution Provider Presentation
For sponsorship opportunities please contact
Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

CROSS-EVENT ROUNDTABLE DISCUSSIONS

17:00-17:30

30 Minute Solution Provider Presentation
For sponsorship opportunities please contact
Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

SKIN & COSMECEUTICALS

17:00-17:30



SENIOR REPRESENTATIVE
Givaudan



LISA MACFARLANE
Co-Founder, The Gut Stuff



ALANA MACFARLANE
Co-Founder, The Gut Stuff
**How can we make the
microbiome and digestive
health mass market**

In a world where the science is incredibly exciting, but also very new, how can we educate the consumer in

17:30-17:55

RACHEL TEITELBAUM (Reserved)
CEO, Hervana Bio
Topic: Women's Health

17:30-17:55

ROUNDTABLE SESSION:
Roundtables are informal, small-group interactive discussions on key topics in the field. Discussion leaders will introduce sub-topics/questions for discussion and roundtable attendees are encouraged to participate actively in the session.

17:30-18:20

Table 1: Microbiome friendly skincare. Are the consumers interested?
MARK O'MAHONY
Technology Scout (Devices & Diagnostics),
Walgreen Boots Alliance

ARTEM GURIEV (Reserved)
Head of TUC SSMU, Professor, Siberian State
Medial University
**Topic: New probiotic delivery system for
topical use**

17:30-17:55

17:30-17:55

a realistic and efficacious, yet engaging way. Equally how can we bridge the healthcare gap for digestive issues to get millennial thinkings about prevention and wellbeing.

SENIOR REPRESENTATIVE

Topic: IBD, Colitis, Metabolic Diseases
Invitation Out

17:55-18:20

17:30-17:55

Continued

SENIOR REPRESENTATIVE

Topic: Women's Health
Invitation Out

17:55-18:20

17:30-18:20

Microbiome friendly skincare is beginning to hit the mainstream. Previously the preserve of niche brands, bigger players are now embracing the concept - Unilever's brand 'Dove' has introduced the mass market to the skin microbiome through a recent UK TV advertising campaign focusing on their 'microbiome gentle' body washes. But is there any scientific evidence that it is necessary for cosmetic products to be microbiome friendly? Are consumers interested or even aware of their skin microbiome? And an important point to consider is that the cosmetics industry does not appear to have a consistent definition of microbiome friendly, or standard testing criteria for microbiome friendly cosmetic products. However, is it now time that everyone embraced their skin microbiome, and made an effort to protect it?



Table 2: Clinical trials addressing the possible efficacy of probiotics in IBD

MARIO GUSLANDI

San Raffaele Scientific Institute

Table 3: Infant Health - TBC
MONIKA SCHAUBECK

Nutritional Scientist, Team Science, Department Research and Development, HiPP



Table 4: Screening, selection and development of ingredients and formulation for their impact on skin microbiota

INGMAR CLAES

CSO, Yun Probiotherapy



Table 5: How to overcome the limiting steps of the Biotech industry?

IHAB BOULAS

Consultant & former CEO, Unibiome

- What are the limiting steps to growth?
- What inspiration to draw from other industries?
- Which resources and advantages are most underexploited?
- In practice, which processes benefit the most from outsourcing?

17:30-17:55

Continued

MILANA ANASH

CEO, Founder, ClearSkin
Topic - Skin Microbiome

17:55-18:20

18:20

Chair's Closing Remarks / End of Day One

18:20-19:20

Room: Shipping Hall

Networking Drinks Reception

08:20-09:00 Room: Shipping Hall Refreshments

MICROBIOME R&D & BUSINESS COLLABORATION

Room: Diamond Room I&II

PROBIOTICS & PREBIOTICS

Room: Goudriaan room I&II

SKIN & COSMECEUTICALS

Room: Leeuwen room I&II



**KEYNOTE ADDRESS:
EMERAN MAYER**

Director, UCLA

Topic: The role of the gut microbiota brain interactions



**KEYNOTE ADDRESS:
AARON DEL DUCA**

Head, Microbiome Platform, DayTwo

Topic: DayTwo's technology, the company and activities in the microbiome space



**KEYNOTE ADDRESS:
LIONEL BRETON**

Scientific Director, L'Oréal Advanced Research
Harnessing the Gut Skin Brain Axis in Health Disease - Short review of a future option

There is increasing evidence suggesting that gut, brain and skin do not act as isolated organs but are involved in a straight relationship. Emerging research has shown that skin microbiota may play a critical role at the interface of all three organs. Therefore, it is not surprising that conditions affecting one organ's microbiota may also have manifestations in the two others. More importantly, a better understanding of the intestinal microflora and its subsequent relationship with our skin may provide new insights into developing unique product candidates that will accurately treat a spectrum of skin disease indications with current unmet needs. As the microbiome continues to enter the scientific mainstream, this multiple complexity organ is largely unexplored, some examples will be presented on gut brain skin connection in some dermatosis and how skin could be involved in some neurodegenerative disorders in the future

09:00-09:40

09:00-09:40

09:00-09:40



HOK BING THIO

Erasmus University Medical Center

Sleep, microbiota and immune system

- Day and night rhythm of microbiota
- Chronobiological impact on microbiota and immune system
- Effects of combined dietary and sleep interventions on immune system



ARJAN NARBAD

Quadram Institute

09:40-10:10

09:40-10:10

09:40-10:10

Invitation Out



MORTEN L. ISAKSEN

Founder and CEO, Bio-Me

PMP™ - A targeted approach to microbiome profiling



Precision Microbiome Profiling (PMP™) was set up to deliver rapid, detailed, accurate and high throughput microbiome profiling. PMP™ makes it possible to obtain direct quantification of the composition of 100+ of the most dominant and relevant bacterial species in fecal samples. The fully validated targeted approach is useful in running large, longitudinal studies and in clinical applications where speed and reproducibility is critical for correct stratification of patients. The presentation will go through some of the recent data from using PMP™ in various clinical settings. Lessons



INGE LINDSETH

Expert Nutrition, MyMicrobiome

Bringing clarity to the fragmented probiotics market - a quality standard



For clinicians and consumers alike, it can be challenging to choose the right probiotic. The opportunity to market probiotic products with specific health claims is limited within the EU/Europe, and the quality of the products on the market is not subjected to quality control by the authorities. This can be of detriment both to clinicians and patients, as well as to vendors who put in the resources to conduct clinical studies to document the efficacy and quality of their product. The MyMicrobiome quality seal "Microbiome-friendly" can be a guidance in this respect. This presentation

10:10-10:40

10:10-10:25

10:10-10:40



SENIOR REPRESENTATIVE

DSM

learnt from analysis of thousands of samples from the HUNT study will also be shared.

details the MyMicrobiome seal, and what it hopes to achieve for the probiotic industry, the health sector and the consumer. MyMicrobiome works with experts in the field and has inhouse facilities to conduct studies of several aspects of probiotic quality.

15 Minute Solution Provider Presentation
For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk / +44 (0) 1865 849841

Continued

10:40-11:50 Room: Shipping Hall Morning Refreshments / One-to-One Meetings / Odd Numbered Poster Presentations

Room: Diamond Room I&II

GUT-BRAIN AXIS



ALETTA KRANEVELD

Professor Interdisciplinary Translational Pharmacology, University of Utrecht, The Netherlands

Parkinson's disease: no guts no glory.

The recently reported leaky gut, intestinal inflammation and changes in the composition of the microbiota in patients point to the relevance of gut-microbiome-immune-brain axis in Parkinson's disease. Based on (pre) clinical data the talk will shed some light on the possible mechanism of the crosstalk between gut and brain in Parkinson's disease. There is a great need for additional therapies for Parkinson's disease that reduce both motor and non-motor symptoms. A poor gut function leads to a poor brain function and vice versa; therefore targeting the microbiota/ gut-immune axis with nutritional interventions or pharmaceutical compounds could be a new approach for the (additional) therapy of neurodegenerative disorders for the treatment of both motor and non-motor dysfunction.

11:50-12:15

Room: Van Oldenbarnevelt Room

DIAGNOSTICS



FINN TERJE HEGGE

CTO and Head of Operations, Genetic Analysis AS
Transition of microbiota analysis from research tool to clinical utility

The GA-map® technology represents a unique approach to microbiome analysis. By combining information from a well-defined set of pre-determined markers it enables highly reproducible and standardized information to be derived from the complex human gut microbiota. This information enables actionable results such as disease progression prediction and treatment response prediction.

11:50-12:15

Room: Goudriaan room I&II

PERSONALISED NUTRITION



JASON BUSH

Adjunct Professor, Department of Biology, Brandon University, USA
Microbiome biomarkers predict human health

improvements in response to resistant starch supplementation

Screening the gut microbiome for biomarkers can help discriminate people who stand to benefit from microbiome-targeting therapies (responders) from those who do not (non-responders). In some cases, coupling prebiotic therapy with other forms of supplementation may help turn non-responders into responders. To this end, we analyzed changes in glucose, cholesterol, and SCFA metabolism in correlation with changes in bacteria in the microbiomes of healthy participants consuming MSPrebiotic® resistant starch. We identified several biomarkers that changed in correlation with health parameters after MSPrebiotic® consumption, including effects on glucose metabolism, cholesterol homeostasis, and butyrate production. These findings highlight the potential value of coupling microbiome testing with selective microbiome interventions to reduce risk factors for disease.

11:50-12:15

Room: Leeuwen room I&II

SKIN & COSMECEUTICALS

YUG VARMA (Reserved)

CEO, Phi Therapeutics

Topic: Skin Diseases - Acne

11:50-12:15



PIERRE LESTAGE
CEO, Neribiom, France
Topic: The gut-brain connection

12:15-12:40



KRISTOFER COOK
CEO, Carbiotix
Multi-sample, longitudinal gut health testing and the generation of functional gut microbiome data

12:15-12:40

- Understanding the natural variability of the gut microbiome and its impact on data accuracy
- Multi-sample, longitudinal gut health testing as a means to improve microbiome data
- Applications of improved microbiome data in the F&B, nutraceutical and therapeutic space



SATU PEKKALA
Academy of Finland Research Fellow, Adjunct professor, University of Jyväskylä
Targeting Faecalibacterium

12:15-12:40

prausnitzii with prebiotic xylo-oligosaccharides (XOS) prevents from non-alcoholic fatty liver disease (NAFLD)
High liver fat content associated with low abundance of Faecalibacterium prausnitzii and administration of F. prausnitzii prevented NAFLD in mice². Because therapeutic microbes are not always accepted to treat humans, we sought to target F. prausnitzii with diet to treat NAFLD in rats. XOS increased F. prausnitzii in vitro and in vivo having minor effects on other gut microbes. Supplemented with high-fat diet (HFD), XOS prevented NAFLD. The underlying mechanisms involved increased hepatic β-oxidation and enhanced mitochondrial respiration. Compared to HFD, HFD+XOS decreased fecal isovalerate and tyrosine levels, metabolites previously associated with NAFLD. Isovalerate associated positively and butyrate negatively with hepatic fat. Our results identified F. prausnitzii as target to treat NAFLD. Finally, we also present a study protocol for prebiotic intervention in humans.



VERONIKA OUDOVA
Co-Founder, S-Biomedic, Belgium
Topic Cutibacterium acnes the main component of the skin microbiota

12:15-12:40

GUT-BRAIN AXIS



GEORGE TETZ
CEO, Human Microbiology Institute
Brain microbiome promotes tau aggregation and Alzheimer's disease

12:40-13:05

Here we report the first evidence for the capacity of extracellular DNA of bacteria that are known to be representatives of brain microbiome in patients with Alzheimer's disease to substantially promote tau misfolding and aggregation. This study suggests the new potential role of the brain microbiota in the initiation and progression of pathological abnormalities responsible for Alzheimer's disease.

STOOL BIOBANKS



SCOTT OLESEN
Scientific Director, OpenBiome
The practice and promise of universal stool banks

12:40-13:05

- Stool banks centralize and standardize collection, processing, and distribution of material for fecal microbiota transplantation (FMT).
- OpenBiome, a non-profit stool bank, provides FMT material to clinicians treating recurrent C. difficile infection, to clinical researchers using FMT as part of clinical trials, and to basic scientists who need standardized, screened material for bench science and animal studies.
- Centralized stool banking can catalyze research by lowering barriers to conducting FMT studies and facilitating comparison of results across studies.

PERSONALISED NUTRITION

MIKE ROGERS
CEO, TrooFoods
Story of a gut health start up through to commercialization

12:40-13:05

SKIN & COSMECEUTICALS



SØREN KJAERULFF
CEO, Lactbio
Targeted screening of living lactic acid bacteria for skincare application, manufacturing and formulation

12:40-13:05

- Screening of lactic acid bacteria with activity against S.aureus
- In vitro and in vivo activity of lactic acid bacteria in skincare applications
- Formulation of living lactic acid bacteria for skincare applications



EDWIN ABELN

Senior Business Development Manager, TNO



Towards a Host - Microbiome

IBD in vitro model for the identification of functional ingredients or drugs

- First results of a novel in vitro IBD model will be presented
- Based on combination of
- i-screen model: 96 wells HTS model of gut microbiome
- InTESTine model: ex vivo human gut wall tissue model

13:05-13:20



JULIA KAPPEL

Customer Success Associate, Zymo Biomics



Standardizing Microbiomics - Removing Bias in Collection, Purification and Analyses

Zymo Research has the goal to provide researchers the best tools for microbiome measurement to ensure standardized microbiomic workflows. The ZymoBIOMICS™ portfolio has been developed to eliminate bias across microbiomics workflows and offers a complete pipeline from start-to-finish for all your microbiome related needs. ZymoBIOMICS™ offers a complete workflow, from sample collection to analysis, which offers streamlined collection, purification, and the first microbial community standards.

13:05-13:20



OLAF LARSEN

Senior Manager Science, Yakult Nederland B.V., Associate Professor, Vrije Universiteit Amsterdam



Probiotics research 2.0

Although the gut microbiota has been studied intensively for the last decades, clinical trials focusing on gut microbiota intervention using probiotics are still in their infancy. Probiotic products and their effects are inherently heterogeneous, hampering a proper comparison between clinical trials. In this lecture, factors underlying this heterogeneity will be discussed. Moreover, possible solutions will be provided with respect to the design of clinical trials to increase the success rate for reaching statistical significance and the development of new, rationally designed, probiotic products.

13:05-13:20



SENIOR REPRESENTATIVE

Clinical Microbiomics

Comprehensive analysis of the skin microbiome using shotgun metagenomics

- Get insights to some of the newest tools available for analyzing the skin microbiome.
- At Clinical Microbiomics we offer full-service microbiome analysis of skin samples. This includes skin-dedicated metagenomics pipelines with optimized DNA extractions, shotgun sequencing, and data analysis to maximize data quality and insights to the skin microbiome.
- Shotgun metagenomics allows comprehensive analysis of both species composition and functional capability of the skin microbiome. Using SNV-based analysis we can furthermore identify and discriminate strain differences of e.g. Staphylococcus aureus and Cutibacterium acnes between healthy subjects and people suffering from conditions such as atopic dermatitis or acne vulgaris.

13:05-13:20

13:20-14:20

Room: Shipping Hall

Lunch / One-to-One Meetings



OLA TUVESON


Head of Process Development and Support, Cobra Biologics



GMP Manufacturing of Live Bacterial Therapeutics

To ensure that safe and effective treatments using Live Bacterial Therapeutic products are brought to the patients the manufacturing needs to be done to the highest quality standards. The special characteristics of these novel products and processes brings challenges in manufacturing, control but also in regulatory compliance. By choosing the correct strategy and addressing a few key elements early in the development process the risk for late failures and delays to market can be decreased.

14:20-14:35



RADHIKA BONGONI


Business Developer, BaseClear B.V.



Pre-pro-postbiotics and role in modulating our microbiome - status & case studies

30 Minute Solution Provider Presentation
For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk / +44 (0) 1865 849841

14:20-14:35



RADHIKA BONGONI

Business Developer, BaseClear B.V.

Pre-pro-postbiotics and role in modulating our microbiome - status & case studies

30 Minute Solution Provider Presentation
For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk / +44 (0) 1865 849841

14:20-14:35



RADHIKA BONGONI

Business Developer, BaseClear B.V.

Pre-pro-postbiotics and role in modulating our microbiome - status & case studies

Microbiome makes us complete. To feed, support and maintain a balance in microbial community is thus pivotal. Therefore the use of pre, pro and post (and many other versions) of biotics have been taking a key role in the industry for human, animal and plant health. Several companies are offering products with specific application targeting a health segment. Consumers should be informed on the scientific backing of such products. This presentation is a snapshot of scientific evidences put forth as case studies for the above applications. Until now the applications of these biotics has been on disease management rather disease cure. This presentation further takes you through the state-of-art genomics technologies that might aid the quest in understanding the role-mechanism of pre-pro-postbiotics for (human) health.

14:20-14:35

14:35-14:50



FRANCOIS BIDET
Vice-President of Business
Development, CSP Technologies

14:50-15:05



EARLY CAREER RESEARCHER PRESENTATION:
SARITA DAM
PhD Candidate in Translational Psychiatry, Radboud University Medical Centre Nijmegen

Brain microbiome promotes tau aggregation and Alzheimer's disease

The impact of the gut microbiota on host physiology and behavior has been relatively well established. Whether changes in microbial composition affect brain structure and function is largely elusive, however. This is important as altered brain structure and function have been implicated in various neurodevelopmental disorders, like attention-deficit/hyperactivity disorder (ADHD). We hypothesized that gut microbiota of persons with and without ADHD, when transplanted into mice, would differentially modify brain function and/or structure. We investigated this by colonizing young, male, germ-free C57BL/6J^{01a}Hsd mice with microbiota from individuals with and without ADHD. We generated and analyzed microbiome data, assessed brain structure and function by magnetic resonance imaging (MRI), and studied mouse behavior in a behavioral test battery.

15:05-15:20

EARLY CAREER RESEARCHER PRESENTATION:
Invitation Out
Topic: gut-brain axis

15:20-16:10



COLETTE SHORTT (Chair)
Director Global Regulatory Affairs,
J&J Consumer

Invitation to Senior Representatives x3

14:20-14:50

Continued

14:50-15:20



EVELIINA MUNUKKA
Research Director, Turku
Microbiome Biobank, University
of Turku, Finland
Turku Microbiome Biobank

(TMB): Could microbiome analyses and microbial-based prevention and therapy be part of the personalized medicine in the future?

- TMB (founded in 2018) aims to the standardized collection, preservation and analyses of human microbial and microbiota samples of various types and from various origin i.e. microbiome library
- Further, microbiota bio-banking enables a well-characterized, time-saving and proper collection of fecal transplants from healthy volunteers. Donors are chosen and screened based on European consensus statement (Cammarota et al. 2017) and their samples are utilized in FMT procedures performed in the hospital district (recurrent C. difficile -infection as indication)
- This library of microbiota samples creates a valuable sample resource and data pool that could be utilized in various medical research questions and further serve as a novel tool in personalized medicine and treatment.

15:20-16:10

CROSS EVENT ROUNDTABLE SESSION:

Roundtables are informal, small-group interactive discussions on key topics in the field. Discussion leaders will introduce sub-topics/questions for discussion and roundtable attendees are encouraged to participate actively in the session.

14:20-14:50

Continued

14:50-15:05



EARLY CAREER RESEARCHER PRESENTATION:
PAULO REFINETTI
CEO and Founder of
REM Analytics

Probiotic "Drug-discovery" finding a treatment for vulvovaginal candidiasis

Recurrent Vulvovaginal candidiasis (VVC) is a chronic condition affecting between 5 and 10% of women worldwide. It is caused by the formation of biofilms in the vagina by Candida yeasts. Candida are normal symbiont of the human, and it is not its presence, but its behaviour that causes the disease. Using a new tool for microbiome profile, 90 women, for a total of 480 vaginal microbiome sample have been analysed. The samples contain both women affected by VVC and others that are not. From the analysis results it is possible to identify signatures of VVC in the microbiome. These signatures represent a first step towards identifying targets for treatment

15:05-15:20

EARLY CAREER RESEARCHER PRESENTATION:
Invitation Out
Topic: Probiotics

15:20-15:45



JEAN-POL WARZEE
President, European Scientific
League for Probiotics - ESLP
**Probiotics quality control:
the ESLP - European
Scientific League for
Probiotics - Experience**

- Numerous food supplements containing probiotics strains such as Lactobacilli, Bifidobacteria,... have been introduced in

14:35-14:50



SENIOR REPRESENTATIVE
DNA Genotek

14:50-15:05

PIM GAL

Senior Clinical Scientist, Centre for Human Drug Research (CHDR), The Netherlands
Topical omiganan recovers dysbiosis but does not improve clinical mild to moderate atopic dermatitis in a phase II randomized controlled trial

15:20-15:45



MIKE HOPTROFF
Senior R&D Manager, Unilever
Product innovation and the skin microbiome
The increasing ability to

measure and characterise the human microbiome creates opportunities and challenges for consumer product innovation bought about by our developing understanding of the microbiome of human skin body and

15:20-16:10

Continued



Table 1: Live bacteria in the consumer skincare market
GEOFF BRIGGS

Technology Scout (Devices & Diagnostics), Walgreen Boots Alliance

Recent advances in microbiome science has led to an explosion in consumer interest and probiotic technologies are now common across the cosmetic skincare market. Live probiotics are common oral supplements, but there are few companies who have extended this technology to topical skincare. The reasons for the slow expansion of the live probiotics in skincare include: consumer acceptance; regulatory and safety considerations, the challenge test; complicated supply chain from factory to consumer; limited shelf-life; difficulty and cost of generating claims; high product price; requirements for Microbiome Friendly probiotic and accessory products. How can we overcome these hurdles? What about the future? Companies are developing commensal species which secrete cosmetic actives directly onto or into the skin. How will this change the skincare market?



Table 2: The microbiome, probiotics and infant health
YEMI ADESOKAN

Co-Founder and CSO, GNUbiotics



Table 3: Protecting and Defending Inventions in the Microbiome Space: Challenges and Strategies
OLGA A. PARTINGTON

Counsel, Sterne, Kessler, Goldstein & Fox P.L.L.C.



Table 4: Infant gut microbiome in term and preterm infants
DAVID KYLE

Chairman and CSO, Evolve Biosystems

15:20-15:45

Europe over the last 10 years. The beneficial effects of probiotics being strain specific, not all the positive results of one strain or association can be generalized to other strains.

- Today all parties involved agree on the need for a "Quality Label" to differentiate quality products from "non-controlled" products. In 2019, ISAPP has co-published a document about the importance of improving end-user trust in the quality of Commercial probiotic products, referring to the ESLP
- After more than 5 years experience in Belgium, the European Scientific League for Probiotics ESLP Quality label internationalisation is taking place in function of the spontaneous demands coming from the different countries (Italy, France, The Netherlands)



MOMU VUYISICH
CSO, Viome, USA
Systems biology approach towards nutritional and LBP therapies for chronic diseases

Viome has created a systems biology platform that collects large amounts of data relevant to chronic diseases. We analyze human stool and blood samples with highly accurate clinical tests, and collect accurate diet and health data. The platform includes machine learning and translational science. We follow a three-step process towards creating nutritional therapies: 1. In our data, we identify molecular patterns associated with specific diseases by performing large observational studies (typically more than 1000 participants), 2. We use machine learning and translational science to create personalized nutrition algorithms that modulate the gut microbiome and human physiology, and 3. We perform randomized controlled trials to demonstrate that our algorithms can shift the gut microbiome and human physiology from disease to health, while positively affecting the symptoms. We have utilized our platform for several diseases/ conditions, and will show progress.

15:45-16:10

15:20-15:45

our appreciation of the interplay between microbiome and skin condition.

15:45-16:10

ANDREA NARDELLI (Reserved)
Farncombe Family Digestive Health Research Institute, McMaster University
Topic: Skin & Microbiome

16:10

Chair's Closing Remarks / End of Day Two

16:10-17:10

Room: Shipping Hall

Evening Activity

08:20-09:00

Room: Shipping Hall

Refreshments

MICROBIOME R&D & BUSINESS COLLABORATION

Room: Diamond Room I&II

**KEYNOTE ADDRESS:
QUN WANG**

Primary Reviewer, Office of Vaccines Research and Review
Center for Biologics Evaluation and Research, U. S. Food and
Drug Administration
Regulatory Aspects of Microbiome-Related Biologic Products

09:00-09:40

PROBIOTICS & PREBIOTICS

Room: Goudriaan room I&II



**KEYNOTE ADDRESS:
MARIA JENMALM**

Professor of Experimental Allergology,
Linköping University

**The role of the infant gut microbiota in
shaping immune and allergy development
during childhood**

The increasing allergy prevalence in affluent countries may be caused by reduced intensity and diversity of microbial stimulation, resulting in an abnormal postnatal immune maturation. The gut microbiota is quantitatively the most important source of microbial stimulation and may provide a primary signal for appropriate immune development, in line with variations in composition and diversity in the first months of life being associated with subsequent allergy development. The maternal microbial environment during pregnancy may also be important in childhood immune programming, and a combined pre- and postnatal supplementation seems to be crucial for the preventive effect of probiotics on infant eczema. Probiotic interventions have so far failed to prevent asthma, however, and further studies are required to identify efficacious asthma and allergy preventive strategies.

09:00-09:40

TOOLS AND TECHNOLOGIES

Room: Leeuwen room I&II



**KEYNOTE ADDRESS:
MIRCEA PODAR**

Distinguished Scientist and Group Leader,
Systems Genetics, Oak Ridge National Laboratory
**Targeted reverse genomics for isolating and
cultivating the human microbial "dark matter"**

A large fraction of the microorganisms that constitute the human microbiome have remained uncultured. Cultivation is important for studying pathogenicity mechanisms, for assessing potential beneficial effects and for understanding how microbes interact with each other and with their human host. We designed an approach based on genomic information generated by culture-independent studies to selectively target, isolate and culture specific organisms from the human microbiome. Antibodies were engineered to bind to predicted membrane proteins, followed by isolation of target cells using flow cytometry cell sorting. This led to the cultivation of several Saccharibacteria and associated actinobacteria. Such targeted, genomics-driven strategies for cultivation will help identifying microbial health-disease determinants and preserving the human microbiome diversity.

09:00-09:40

Room: Diamond Room I&II

CANCER



ROMAIN DAILLÈRE

Head of Preclinical Research,
EverImmune

**Improving cancer treatment
through Oncobax-based
therapeutics**

- Intestinal commensals dictate our systemic and anticancer immunity
- Harnessing the microbiome for the discovery of diagnosis and therapeutic tools in cancer is key for modulating the clinical outcome of anticancer regimens
- EverImmune is developing Oncobax-based therapeutics to improve the efficacy of anticancer treatments

9:40-10:10

Room: Van Oldenbarneveldt Room

BUSINESS COLLABORATION -
REGULATIONS AND INVESTMENT

LARS ENGSTRAND

Professor, Director Clinical Genomics Facility &
Centre for Translational Microbiome Research,
Karolinska Institutet, Sweden

**Topic: Successful collaborations between
academia and companies in GI-related
disorders, reproductive medicine and cancer**

9:40-10:10

Room: Goudriaan room I&II

EARLY LIFE AND INFANT



GER RIJKERS

Professor in Biomedical and
Life Sciences, University of
Roosevelt, The Netherlands

**Topic: Setting the stage for
long and healthy life**

9:40-10:10

Room: Leeuwen room I&II

TOOLS AND TECHNOLOGIES



MARK WEBBER

Group Leader, Quadram
Institute

**Rationale design of improved
probiotics and microbiome
therapeutics**

- Modifying bacterial communities is crucial to make targeted improvements to health, currently selection of probiotics or microbiota interventions is based on trial and error.
- We have developed a new functional genomics tool "TraDIS-Xpress" which allows all bacterial genes to be tested for importance in any condition.
- This allows rational selection of strains with improved performance in microbiome (and other) applications.

9:40-10:10



BENJAMIN LELOUVIER 

CSO, Vaiomer
The blood microbiome: new source of biomarkers for infectious and cardiometabolic diseases

Thanks to optimized 16S qPCR and 16S metagenomic sequencing pipelines, Vaiomer can analyze quantitatively and qualitatively blood and tissue microbiome. Vaiomer has demonstrated the existence of a highly diversified blood microbiome in healthy human donors and shown the associations between changes in the blood microbiome and different non-infectious diseases. These associations help to understand the role of bacterial translocation in the diseases and find new sources of diagnosis and companion biomarkers. These assays were primarily designed to analyze bacterial DNA in blood and tissue of healthy donors and therefore their signal to noise ratios are high and they are also capable of detecting and characterizing bacterial infection in patients' samples with really high sensitivity.

10:10-10:25

10:25-10:40

15 Minute Solution Provider Presentation
 For sponsorship opportunities please contact
 Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

10:10-10:40

30 Minute Solution Provider Presentation
 For sponsorship opportunities please contact
 Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

10:10-10:40

30 Minute Solution Provider Presentation
 For sponsorship opportunities please contact
 Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

10:10-10:40

30 Minute Solution Provider Presentation
 For sponsorship opportunities please contact
 Gavin Hambrook at
gavin@globalengage.co.uk / +44 (0) 1865 849841

10:40-11:50 Room: Shipping Hall Morning Refreshments / One-to-One Meetings / Even Numbered Poster Presentations



DAVID HUGHES
 Assistant Professor of Cancer Epidemiology, UCD Conway Institute, University College Dublin, Ireland

Immune responses to bacterial antigens and association with colorectal cancer risk in a large European cohort study
 Gut microbiome dysbiosis is increasingly implicated in colorectal cancer (CRC) aetiology. However, there is a lack of prospective data on the potential association of candidate carcinogenic microbes with CRC development risk. We measured antibody responses in a multiplex assay of 44 antigens from *Streptococcus gallolyticus*, *Fusobacterium nucleatum*, *Helicobacter pylori*, *pks+Escherichia*

11:50-12:15

11:50-12:15



KRISTIN WANNERBERGER
 Director R&D Alliance Management, Ferring Pharmaceuticals, Switzerland

Microbiome Alliances in Ferring

- CTMR- collaboration with the Karolinska Institutet Stockholm, Sweden
- Bacteriophages collaborations

11:50-12:15

MIGUEL GUEIMONDE FERNÁNDEZ
 Research Scientist, IPLA-CSIC
Establishment of the gut microbiome in early life: A target for promoting later health

- The gut microbiota plays a key role in the maintenance of human health and, therefore, the microbial colonization of the newborn poses important implications for later health, with accumulating evidence supporting the key role of the neonatal period for the microbiota-induced maturation of the host.
- The initial establishment of the microbiome and its further development are affected by several factors. Unfortunately, our knowledge on this early process is still limited. Thus understanding the development of the microbiota in infants is of critical importance.

11:50-12:15

MATTHEW GERDING
 Investigator II, Novartis Institute for BioMedical Research (NIBR)
Microbiome derived Therapeutics a new class of drugs

- Current approaches to develop microbiome therapeutics
- Challenges involved in developing microbiome therapeutics
- Future of microbiome therapeutics

11:50-12:15

coli (expressing colibactin), and enterotoxigenic Bacteroides fragilis in serum samples taken before cancer diagnosis. Tested subjects were from a cohort of 492 CRC cases and 492 matched controls nested in the European Prospective Investigation into Cancer and Nutrition (EPIC). Antibody responses to antigens of S. gallolyticus, H. pylori, plus E. coli and B. fragilis in combination were significantly associated with CRC risk, while those to F. nucleatum were not linked to CRC development.

11:50-12:15

Continued

**CROSS EVENT
ROUNDTABLE SESSION:**

Roundtables are informal, small-group interactive discussions on key topics in the field. Discussion leaders will introduce sub-topics/questions for discussion and roundtable attendees are encouraged to participate actively in the session.



Table 1: The microbiome and women's fertility

NICOLETTA DI SIMONE
Professor Obstetrics and Gynecology, Catholic University, Rome, Italy

- **Gut Microbiota** - Researches have suggested a classification of people in three different classes of microbial enterotypes, characterized by specific digestive functions. This classification might have the potential to be clinically useful as an indicator of the risk of susceptibility in developing diseases.
- **Vaginal Microbiota** - Recent studies have shown reduced Lactobacilli and an increased bacterial diversity in patients with preterm birth. These observations suggest that early vaginal cultures, that show absence of Lactobacillus and a polymicrobial vaginal colonization, might be risk factors for obstetrical complications.
- **Endometrial microbiota.** It regulates the activity of endometrial immune cells influencing embryo implantation, extravillous trophoblast migration and spiral arteries remodeling. Therefore a classification based on bacterial patterns would be useful to develop a microbiota-based diagnosis, personalized therapies and personalized treatments

12:15-13:05

12:15-13:05

**PANEL DISCUSSION:
Investment - TBC**



MALCOLM KENDALL
Co-Founder & CEO, Microbiome Insights, Inc



ERIC DE LA FORTELLE
Venture Partner, Seventure Partners

11:50-12:15

- Understanding the establishment of the microbiome in early life promises allowing the development of intervention strategies, such as the use of probiotics and/or prebiotics, for assisting the process of establishment of the microbiome to reduce the later risk of disease.



DAVID KYLE
Chairman and CSO, Evolve Biosystems
Topic: The Natural Symbiosis Between B. infantis and HMO Provides Colonization Protection for the Early Infant Gut

12:15-12:40




YEMI ADESOKAN
Co-Founder and CSO, GNUbiotics
HMOs: Functionality through Diversity, Natures Way

12:40-13:05

11:50-12:15

Continued



JONATHAN FRIEDMAN
Senior Lecturer, Department of Plant Pathology and Microbiology, Hebrew University, Israel

High-throughput screening for beneficial synthetic microbial communities

- High-throughput screening can be a powerful tool for generating beneficial microbial communities, but is currently technically challenging.
- We have developed a nanodroplet based platform for easy and rapid screening ~100,000 randomly-assembled microbial communities.
- Our platform can be adopted for numerous applications across basic and applied microbial ecology including pathogen suppression, pollutant degradation, and production of valuable natural products.

12:15-12:40



LEO MELCHERS
Strategic Partnerships, Biosortia Pharmaceuticals
Small Molecule Mining of the Aquatic Microbiome for Therapeutics & Agriculture

- Technological breakthroughs now allow obtaining natural microbiome and interrogating the actual hidden chemistry along with genomics data.
- Current and advancing technologies simplify the mining of a complex mixture of signaling small molecules of the aquatic microbiome.
- Therapeutic and Agricultural opportunities emerging from natural environmental microbiome habitats.

12:40-13:05

12:15-13:05




Table 2: Bio-banking of microbial/microbiota & Personalised bacterial therapy based on bio-banking - TBC
EVELIINA MUNUKKA
 Research Director, Microbiome Biobank, University of Turku




Table 3: Sleep, microbiota and immune system - TBC
HOK BING THIO
 Erasmus University Medical Center

Table 4: Title TBC
ROBERTO GRAU
 Assistant Professor, School of Biochemistry and Pharmacy, National University of Rosario, Argentina

12:15-13:05

12:40-13:05

Continued

12:40-13:05


Continued

12:40-13:05

Continued

13:05-14:05 Room: Shipping Hall Lunch / One-to-One Meetings

14:05-14:30



KAITLIN WADE
 Elizabeth Blackwell Institute
 Research Fellow in Integrative Epidemiology, University of Bristol, UK

Application of human genetics to understand the causal link between the gut microbiome and colorectal cancer
 Recent studies provide evidence supporting an association between the human gut microbiome and colorectal cancer (CRC). However, few findings have translated between model organisms and human studies have been unconvincing in their ability to offer causal evidence. Mendelian randomization (MR) is a method that uses human genetic variants as instruments to proxy for a clinically relevant trait to improve causal inference. We used MR to interrogate the causal impact of the gut microbiome on CRC combining data from the Flemish Gut Flora Project and two German cohorts (n=3890) with the Genetics and Epidemiology of Colorectal Cancer Consortium (n=120328). We found evidence that presence of a genus within a certain order of bacteria increased the risk of CRC by 8% (95% CI: 2-15%; P=0.02).

14:05-14:30

14:05-14:30




SIMONE MACCAFERRI
 Senior Research Advisor,
 Bioeconomy - Research and Competitive Funding Division,
 Alma Mater Studiorum
 Università di Bologna, Italy

Exploiting the microbiomes: research policies and funding to translate innovation into practice

- Overview of the main funding opportunities related to microbiome in EU research funding framework and showcase of major actions and strategies currently ongoing in the field
- How to ensure facilitation for industrial exploitation of results
- Microbiome in the context of the European Bioeconomy Strategy: the role of policy instruments to foster the future of microbiome research

14:05-14:30

14:05-14:30




LYDIA MAPSTONE
 CEO, BoobyBiome

The breast milk microbiome: Community dynamics and cultivability of keystone microbial species to improve preterm health

Human breast milk harbours a diverse and unique community of microbes, which play a major role in seeding the early stage infant gut microbiome. The ability to select keystone species from milk will be assessed, which will inform probiotic design. This will be important for infants without access to breast milk, who are prone to microbiome linked disease. BoobyBiome is designing a probiotic supplement for infants that will contain clinically designed bacterial strains based on our findings from examining human milk microbial communities.

14:05-14:30

14:05-14:30



JOHAN BENGTSSON PALME
 Assistant Professor, Centre for Antibiotic Resistance Research,
 Institute of Biomedicine, University of Gothenburg, Sweden

Deciphering the genetic mechanisms behind microbial interactions in microbiomes
 The great complexity of microbial communities makes it nearly impossible to identify the mechanisms behind interactions between their players. Akin to how model systems such as Escherichia coli have driven our understanding of biology also outside of these specific models, simplified model communities can help us decipher the genetic basis of microbial interactions. Recent model community development and rapid advancement of large-scale technologies for studying their genes are now finally lending us insights into community interactions. In this talk, I will specifically highlight how we use model community systems and large-scale sequencing approaches to understand the genetic basis of community stability and the ability to invade microbial communities. The results have impact on our understanding of human dysbiosis and its links to various diffuse diseases.

14:05-14:30

SENIOR REPRESENTATIVE (Reserved)

Merck

Topic: The human microbiome and cancer

14:30-14:55

SENIOR REPRESENTATIVE

Topic: Cancer & the Microbiome

Invitation Out

14:55-15:20



OLGA A. PARTINGTON

Counsel, Sterne, Kessler, Goldstein & Fox P.L.L.C.

Protecting and Defending Inventions in the Microbiome Space: Challenges and Strategies

A robust and defensible intellectual property (IP) estate can be the cornerstone of an innovative company's value. As businesses operating in the microbiome space move more into mainstream commerce, a proactive approach to IP protection is imperative. Strategies for patent protection in this space can differ from the traditional small-molecule- and antibodies-based inventions. In addition, the choice between patent protection versus trade secret can make or break the company's IP value. This talk will address the unique challenges and nuanced strategies associated with obtaining IP protection in the microbiome space in the United States. The discussion will also provide strategies for obtaining patent portfolios better positioned to withstand the scrutiny of inevitable post-issuance challenges.

14:30-14:55



COLETTE SHORTT

Director Global Regulatory Affairs, J&J Consumer

Considerations for Nutritional Microbiome Products

- Regulations

14:55-15:20



GREGORY BUCK

Professor, Microbiology & Immunology & Computer Science, Virginia Commonwealth University

The microbiome of the female reproductive tract, pregnancy and women's health

The microbiome of the female reproductive tract has a significant impact on women's health and pregnancy. Generally thought of as being dominated largely by Lactobacillus species, it is becoming increasingly obvious that the healthy female vaginal microbiome can be quite complex. Hallmarks of a healthy reproductive tract vary across racial and socioeconomic borders in ways that are only now becoming clearer. In pregnancy, the microbiome of the female reproductive tract seems to change in population specific patterns across trimesters, and early microbiome-associated biomarkers may become predictors of adverse pregnancy outcomes, including but not limited to preterm birth. These studies may lead to new strategies for intervention and reduce the burden of an less favorable vaginal microbiome on women's health and well-being.

14:30-14:55

14:55-15:20

FRANCESCO SAVINO (Reserved)

Department of Pediatrics, Universitaria Città della Salute e della Scienza di Torino Italy

Topic: Early Life and Infant



IHAB BOULAS

Former CEO, Unibiome

Unknown tools to increase profits overnight

- By ignoring a number of powerful tools, companies operate sub-optimally
- How to find a needle in a haystack
- How to alleviate logistic burden

14:30-14:55

14:55-15:20

SANJAY VASHEE (Reserved)

Associate Professor, J. Craig Venter Institute

Topic: Tools and Technologies for successful Microbiome research

15:20

Conference Close

MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). There is no charge to any attendee to present a poster.

POSTER COMPETITION - CLOSING DATE 27TH APRIL 2020

- Submit your entry prior to the closing deadline (1 entry per person)
- Four Entries for the Microbiome and Probiotics R&D and Collaboration Forum will be selected by the judges
- The winners of the poster competition will be given a 15-minute speaking position on the conference agenda and notified in advance of the meeting
- The judge(s) will make the decision based on the abstract(s) submitted
- Each winner will also receive a certificate from the organisers
- Representatives from solution provider organisations are not eligible to enter the competition but are welcome to present posters at the meeting as normal

Submission instructions

We will require the form (downloadable below) to be submitted by the 27th April to enter the competition. To simply have your poster at the meeting, submissions must be made no later than 1st May. This is the formal deadline however space is another limiting factor so early application is recommended. Therefore please contact us with any questions you have as soon as possible.

www.global-engage.com/wp-content/uploads/2019/12/MRAD20-Poster-Abstract-Submission-Form.docx





Postillion Convention Centre WTC Rotterdam

Parkeergarage Beurs-WTC,
Rodezand 19,
3011 AM Rotterdam

www.postillionhotels.com/en-gb/conferenties-events/rotterdam-convention-centre

In the vibrant heart of the Rotterdam metropolis: you cannot get more central than this. Wherever you are in the world, a World Trade Center is a special place. It is an (inter)national corporate community, in a unique building that meets the highest standards. From high-spec office space to high-tech meeting rooms, shops, restaurants and a wide range of additional services.

- A non-stop high-speed train runs between Rotterdam and Schiphol (Amsterdam airport) every 20 minutes. The journey time is 20 minutes. Cost €22 Euros
- Located in the city centre (surrounded by shops, architecture, museums, restaurants and the Port of Rotterdam)
- Walking distance from the international train station
- Rotterdam - The Hague airport with flights to at least 30 international destinations is a short taxi ride
- A large number of parking facilities can be found in the area
- A wide variety of hotels are within walking distance. (Details will be sent to you in your welcome letter when you register)

